DiaMedica Therapeutics Announces 2018 Financial Results and Provides Corporate Update – Nasdaq

Dosed first patients in Phase Ib study of DM199 in Chronic Kidney Disease patients under an IND accepted by the FDA in 2018; Plan to initiate Phase.